绥美凯会耐药吗？

/ Dolutegravir is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014. Subsequently, on January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation dolutegravir (Triumeq), which is based on the new generation integrase inhibitor dolutegravir (DTG) and is used to treat HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Will Suimeikai be resistant?

According to Medical Companion Travel, Suimeikai will develop drug resistance. The resistance time a patient develops after taking Suimeikai depends on the patient himself. There is no clear standard for the resistance of the human body. If the patient's physical condition is very good, the resistance time will also increase.

Notes: 1. Transmission of HIV. Although viral suppression with antiretroviral therapy has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be excluded. Precautions should be taken to prevent transmission in accordance with national guidance. 2. Hypersensitivity reaction. Both abacavir and dolutegravir carry the risk of triggering a hypersensitivity reaction (HSR) and share some common characteristics, such as fever and/or rash and other symptoms indicating involvement of multiple organs. It is clinically impossible to determine whether abacavir or dolutegravir is responsible for a hypersensitivity reaction that occurs with Trimeq. Hypersensitivity reactions have been observed to occur more commonly with abacavir, some of which can be life-threatening and, in rare cases, fatal if not managed appropriately. Patients who test positive for the HLA-B5701 allele are at higher risk of developing abacavir hypersensitivity reactions. However, abacavir hypersensitivity reactions are reported less frequently in patients who do not carry this allele.

Therefore, the following measures should be followed: HLA-B5701 status must be confirmed before starting treatment. Patients with a positive HLA-B5701 status, or patients with a negative HLA-B5701 status who had a suspected abacavir hypersensitivity reaction when previously receiving an abacavir-containing treatment regimen, should not be treated with Trimax.

If a hypersensitivity reaction is suspected, Suimika should be discontinued without delay, even if the HLA-B5701 allele is not present. If a hypersensitivity reaction occurs and treatment with Trimax is not discontinued immediately, a life-threatening reaction may result. Clinical status, including hepatic aminotransferases and bilirubin, should be monitored. After discontinuing Trimax due to suspected hypersensitivity reaction, Trimax or any other medicine containing abacavir or dolutegravir should never be restarted. After a suspected hypersensitivity reaction to abacavir, symptoms may return within hours if abacavir-containing medicines are restarted. Relapses are generally more severe than the initial episode and may include life-threatening hypotension and death. To avoid re-dosing abacavir and dolutegravir, patients with suspected hypersensitivity reactions should be instructed to discard remaining abacavir/dolutegravir tablets.